Standard usage and dosage of adagrasib (Krazati) and matters needing attention during medication

Adagrasiib (Krazati) is an oral targeted drug mainly used to treat patients with KRAS G12C mutation-positive non-small cell lung cancer. According to the latest instructions, the standard dosage is 600 mg twice a day, taking the whole tablet orally. It is recommended to take the medicine at a fixed time to maintain stable blood concentration. The tablets should not be crushed or chewed, and should not be taken with high-fat meals to avoid affecting absorption and efficacy.

During the medication process, patients must strictly follow the doctor's instructions and are not allowed to increase or decrease the dosage or stop medication at will. If obvious side effects or poor tolerance occur, the doctor may recommend temporarily discontinuing the medication or adjusting the dose based on the specific situation. Dosage adjustments must be made under the guidance of a physician to ensure efficacy while reducing the risk of adverse reactions.

Common side effects include diarrhea, rash, fatigue, nausea, and increased liver function indicators. During the period of medication, blood routine, liver function and kidney function should be monitored regularly. If abnormal indicators appear, seek medical attention in time. Maintaining good living habits, a balanced diet and adequate water intake can help relieve gastrointestinal and skin discomfort.

In addition, special attention should be paid to drug interactions when adagrasib is used in combination with other drugs. In particular, simultaneous use with CYP3A4 strong inhibitors or inducers may lead to significant changes in blood concentration, thereby affecting efficacy or increasing the risk of toxicity. Therefore, patients should arrange a reasonable medication regimen under the guidance of a doctor, and regularly review blood drug concentrations and liver and kidney functions to ensure treatment safety and stable efficacy.

Reference materials:https://www.drugs.com/